Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.

Robinson AN, Tebase BG, Francone SC, Huff LM, Kozlowski H, Cossari D, Lee JM, Esposito D, Robey RW, Gottesman MM.

Drug Metab Dispos. 2019 Jul;47(7):715-723. doi: 10.1124/dmd.118.086181. Epub 2019 May 2.

2.

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2018 Oct 2;9(77):34641. doi: 10.18632/oncotarget.26214. eCollection 2018 Oct 2.

3.

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2017 Aug 4;8(43):73387-73406. doi: 10.18632/oncotarget.19945. eCollection 2017 Sep 26. Erratum in: Oncotarget. 2018 Oct 2;9(77):34641.

4.

Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.

Huff LM, Sackett DL, Poruchynsky MS, Fojo T.

Cancer Res. 2010 Jul 15;70(14):5870-9. doi: 10.1158/0008-5472.CAN-09-4281. Epub 2010 Jun 29.

5.

A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T.

Clin Cancer Res. 2010 Mar 1;16(5):1634-41. doi: 10.1158/1078-0432.CCR-09-0379. Epub 2010 Feb 23.

6.

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

To KK, Polgar O, Huff LM, Morisaki K, Bates SE.

Mol Cancer Res. 2008 Jan;6(1):151-64. doi: 10.1158/1541-7786.MCR-07-0175.

7.

Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.

Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, Cox NJ, Bates SE, Ratain MJ.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6788-95.

8.

Characterization of gene rearrangements leading to activation of MDR-1.

Huff LM, Lee JS, Robey RW, Fojo T.

J Biol Chem. 2006 Dec 1;281(48):36501-9. Epub 2006 Sep 5.

9.
10.

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

Chen KG, Wang YC, Schaner ME, Francisco B, DurĂ¡n GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI.

Cancer Res. 2005 Oct 15;65(20):9388-97.

11.

The effects of age and dementia of the Alzheimer's type on phonological false memories.

Sommers MS, Huff LM.

Psychol Aging. 2003 Dec;18(4):791-806.

PMID:
14692865
12.

Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).

Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE.

Cancer Biol Ther. 2002 Nov-Dec;1(6):696-702.

PMID:
12642696

Supplemental Content

Support Center